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Abstract   
Pharmacists are trusted health professionals. Many patients use over-the-counter (OTC) medications 
and are seen by pharmacists who are the initial point of contact of allergic rhinitis management in 
most countries. The role of pharmacists in integrated care pathways (ICPs) for allergic diseases is 
important. This paper builds on existing studies and provides tools intended to help pharmacists 
provide optimal advice/interventions/strategies to patients with rhinitis. The ARIA-pharmacy ICP 
includes a diagnostic questionnaire specifically focusing attention on key symptoms and markers of 
the disease, a systematic Diagnosis Guide (including differential diagnoses) and a simple flowchart 
with proposed treatment for rhinitis and asthma multimorbidity. Key prompts for referral within the 
ICP are included. The use of technology is critical to enhance the management of AR. However, the 
ARIA-pharmacy ICP should be adapted to local health care environments/situations as regional 
(national) differences exist in pharmacy care. 
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Introduction 
Allergic diseases such as rhinitis and asthma are common, complex conditions, associated with 
allergen-specific IgE and non-allergic mechanisms (1, 2). These diseases represent an enormous 
burden associated to personal, medical, and social costs as well as impairment in work productivity 
(3-6), impacting health and social inequalities in all age groups (7).  
Allergic rhinitis (AR) is a highly diverse chronic disease spanning from mild intermittent rhinitis to 
Severe Chronic Upper Airway Disease (SCUAD) (8). There is evidence that the condition is sub-
optimally managed with several unmet needs which include:  
• Understanding the different endotypes (rhinitis and asthma) (9) and the presence of different 
phenotypes of AR and multi-morbidities which can impact AR and asthma control,  
• Improving AR diagnosis using modern technology (10),  
• Delivering management strategies and interventions which address suboptimal rhinitis and 
asthma control arising not only from suboptimal medical management/treatment, but as a 
result of a range of cultural and/or social barriers (8, 11),  
•  Assessing risk factors such as allergens and pollutants to incorporate them into management 
strategies, using technologies that promote sentinel networks within multidisciplinary care 
pathways (i.e. integrated care pathways (ICPs)) (12), 
• Stratifying patients, based on their needs, in order to optimize the use and effectiveness of ICPs 
(13), and  
• Promoting multidisciplinary teams within integrated ICPs, endorsing innovation in clinical trials 
and encouraging patient empowerment.     
ICPs are structured multidisciplinary care plans which detail essential steps in the care of patients. 
They promote the translation of guidelines into local protocols and their subsequent application to 
clinical practice. They empower patients and their carers (health and social). ICPs differ from practice 
guidelines as they are utilized by a multidisciplinary team and have a focus on the quality and 
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coordination of care. Pharmacists are at the forefront of ICPs for AR. An ICP is intended to act as a 
guide to treatment. 
This paper builds on existing studies and provides tools intended to help pharmacists provide 
optimal advice/interventions/strategies to patients with AR. The ARIA-Pharmacy ICP includes a 
diagnostic questionnaire specifically focusing attention on key symptoms and markers of the 
disease, a systematic Diagnosis Guide (including a differential diagnosis) and a simple flowchart with 
proposed treatment for rhinitis and asthma multimorbidity. Key prompts for referral within the ICP 
are included. The use of technology is critical to enhance the management of AR. However, the 
ARIA-pharmacy ICP should be adapted to local health care environments/situations.  
 
1-  Pharmacist challenge in allergic rhinitis 
Considering the challenges associated with AR and the identified needs, it is clear that the 
pharmacist has a role for AR management in practice, through a guided change management 
process. This is both within the scope of pharmacy practice and in line with future models of 
integrated care. Pharmacists are ideally placed to manage this extremely important link in care 
pathways.  
Worldwide, pharmacists receive advanced training in basic and clinical sciences. Given the 
importance of self-medication in many allergic diseases and in iatrogenic disease, pharmacist 
interventions are well placed to maximize the benefits and minimize the adverse events associated 
with pharmacotherapy. This is particularly important in AR and asthma multi-morbidity (14) as well 
as in the elderly patients, a large number of whom present with allergic diseases in combination with 
other chronic diseases (15). Moreover, most AR medications are available over the counter (OTC) 
(16-19). The impact of the switch from prescription to OTC medications has been profound in AR 
(20) with a significant impact on cost and health utilization reduction (21). Therefore, as trusted 
healthcare professionals in the community, pharmacists are well placed to play a critical role 
identifying the symptoms of AR, recommending appropriate OTC treatment (22-24) and integrating 
ICPs into health care teams.  
Pharmacists (along with patients, clinicians and other healthcare professionals (HCPs)) are faced with 
the relative merits and downsides of the various treatment options. Clinical practice guidelines for 
AR management developed over the past 20 years have improved the care of AR patients (25) and 
provide a critical framework for AR management (25-27). These guidelines are becoming particularly 
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important for HCPs in primary care since, in most countries, few AR patients consult a specialist 
physician. In fact, many patients with AR under-recognize their condition (4) and, as such, do not 
even consult a physician (28). A large proportion of AR patients actually self-manage their condition 
(5, 6)  and the pharmacist is often the first HCP to whom a person with nasal symptoms presents (29, 
30). This further strengthens the important role of pharmacists within multidisciplinary health care 
teams, acting at different steps of the ARIA-Pharmacy ICPs (23, 31-33). 
The specific role of pharmacists within ICPs can been evidenced through several strategies that have 
been initiated (34) or completed in the AR management in the pharmacy, and in studies confirming 
the important impact of pharmacist interventions on AR outcomes (18, 35-43). The specific areas of 
pharmacist impact in AR are summarized in Table 1. 
2- ARIA 
Allergic Rhinitis and its Impact on Asthma (ARIA) commenced during a World Health Organization 
(WHO) workshop in 1999 (44), and was further developed by the WHO Collaborative Center for 
Rhinitis and Asthma (2002-2013). This work has been undertaken in four phases, which are briefly 
summarized below: 
• Phase 1: The initial goals were (i) to propose a new AR classification, (ii) to promote the concept 
of multi-morbidity in asthma and rhinitis and (iii) to develop guidelines with all stakeholders that 
could be used globally for all countries and populations. ARIA has been disseminated and 
implemented in over 70 countries globally (7, 45-54), and was revised and updated in 2008 (7). 
• Phase 2: Focused on transparent reporting of guidelines to facilitate understanding and 
acceptance using the GRADE approach (25, 26).  
• Phase 3: MASK (Mobile Airways Sentinel Network), an ARIA initiative, is focusing on (i) the 
implementation of multi-sectoral ICPs (ii) using emerging technologies (iii) with real-world data 
(iv) for individualized and predictive medicine (v) in rhinitis and asthma multi-morbidity, (vi) by a 
multi-disciplinary group or by patients themselves (self-care) using the AIRWAYS ICPs algorithm 
(Figure 2) (vii) across the life cycle (12, 55).  
• Phase 4 concerns change management strategies (56). ARIA-pharmacy ICPs represent one of the 
change management steps.   
ARIA in the pharmacy (23) and its pocket guide were published in 2004 to help pharmacists with the 
management of AR symptoms and their impact on asthma. Most recommendations proposed in 
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2004 are still valid but should be updated due to the larger number of medications now available 
OTC. In the initial approach, ICPs were not considered and the new information and communication 
technology (ICT) was not available. 
 
3- Integrated care pathways for allergic rhinitis  
a. AIRWAYS ICPs 
The B3 Action Plan of the European Innovation Partnership on Active and Healthy Ageing (EIP on 
AHA, DG Santé and DG CONNECT) (57) promotes integrated care models for chronic diseases, 
including the use of remote monitoring. Based on this initiative and its aims to produce evidence-
based translational outcomes, an ICP for airways disease (AIRWAYS ICPs) was developed. Its aim was 
to launch a collaboration to develop practical multi-sectoral ICPs (i) to reduce chronic respiratory 
disease (CRD) burden, mortality and multi-morbidity, (ii) to improve education of all stakeholders, 
(iii) to improve work productivity, (iv) to promote AHA and (v) to reduce inequities in all populations 
globally (58).   
AIRWAYS ICPs considers a multi-disciplinary approach to AR and asthma multi-morbidity 
management with the pharmacist at the forefront of the algorithm (Figure 1). A very large number 
of AR patients use OTC drugs (23) and are treated in community pharmacies while the vast majority 
of patients who visit primary care physicians or specialists have moderate/severe rhinitis (59-63).  
However, pharmacy practice varies widely across countries and ICPs should be tailored to the local 
needs taking into account cultural barriers, socio-economic considerations, health care practices and 
available OTC medications. 
b.  mHealth in the management of AR incorporating technology for 
better AR management 
mHealth including apps running on consumer smart devices (i.e. smartphones and tablets) has the 
potential to profoundly impact healthcare (64). An evidence-based app for use in AR management is 
available. MASK (Mobile Airways Sentinel network) (ARIA Phase 3) is an app, i.e. an information and 
communications technology (ICT) system, centred around the patient (12, 55, 65). It is an 
implementation tool of the European Innovation Partnership on Active and Healthy Ageing (EIP on 
AHA (57, 66)). A mobile phone App (available for Android and iOS), the Allergy Diary, launched in 23 
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countries and 17 languages (55, 67), is associated with an inter-operable tablet for physicians and 
other HCPs (65), using visual analogue scale (VAS), the same simple common language to manage AR  
((68, 69).   
The Allergy Diary also encompasses questions relating to the patient’s experience of AR symptoms, 
an additional quality of life questionnaire (EQ-5D (EuroQuol)) (70-72), and a validated tool for 
simultaneously assessing AR and asthma control (Control of Allergic Rhinitis and Asthma Test 
(CARAT)) (73-76). These can be used for self-monitoring or can be used for inclusion into clinical 
trials. The Allergy Diary is an integrated approach and can be used by patients in the management of 
their AR, by HCPs in assisting and guiding management and by researchers to collect large-scale 
population data on AR status and management globally. 
c. Clinical decision support system: additional resource for pharmacists 
Clinical decision support systems (CDSS) are software algorithms that advise HCPs on diagnosis and 
management of patients based on the interaction of patient data and medical information, such as 
prescribed drugs. CDSS should be based on the best evidence to aid patients and HCPs in shared 
decision making.   In a prospective intervention study, a computerized pharmacy CDSS for the 
counselling of patients with AR was tested. The results showed that pharmacists omitted many 
questions mandatory to assessing whether self-medication is appropriate, showing the importance 
of the CDSS (77). 
An AR CDSS (MASK CDSS) is available for pharmacists as a companion to the Allergy Diary  (ARIA 
Allergy Diary Companion) (12, 55). The ARIA Allergy Diary Companion is based on an algorithm to aid 
in the selection of pharmacotherapy for patients with AR and to stratify their disease severity (55). It 
uses a simple step-up/step-down individualized approach to AR pharmacotherapy and may hold the 
potential for optimal control of symptoms, while minimizing side-effects and costs. Its use is 
encouraged for pharmacists, however its application may vary depending on the availability of 
medications in the different countries and on resources.   
4- Management of allergic rhinitis in the pharmacy: ARIA-
pharmacy ICP 
Based on the ICP concept, mHealth and CDSS, ARIA Phase 4 has developed an ICP for Community 
Pharmacy, to assist pharmacists in the management of AR within the AIRWAY ICPs framework 
(Figure 1).   In summary, this frames the role of the pharmacist in AR across 4 domains:  
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• Recognition and classification of allergic rhinitis symptoms. As pharmacists are often the 
health care location at which people with AR either initially present or most frequently 
present, recognizing and classifying AR becomes critical. 
• Identification of AR-related ocular symptoms and asthma: Pharmacist’s role includes not 
only assisting in confirming that AR is present but will allow for the identification of possible 
other conditions and patients at risk, requiring immediate referral to a general practitioner.  
• AR treatment: Initiating/recommending optimal treatment, as medication management has 
been proven to be the most effective way of managing AR (25, 26). 
• Patient support and AR monitoring over time: Supporting the patient with appropriate 
evidence-based education, self-management support and long term monitoring over time.  
These 4 domains are discussed below: 
a. Recognition and classification of allergic rhinitis symptoms 
Although AR diagnosis requires tests to confirm the allergic sensitization, most patients self-diagnose 
their AR, consulting pharmacists without a doctor diagnosis of AR.  Several questionnaires are 
available for the screening of allergic diseases (78, 79). Most AR patients have multiple nasal 
symptoms (rhinorrhoea, sneezing, nasal pruritus and obstruction), a large percentage have ocular 
symptoms (ocular tearing, redness and pruritus) and many have asthma. In order for pharmacists to 
evaluate the possibility of screening for AR, a series of questions should be asked to patients with 
nasal symptoms. The questionnaire in Table 2, while it will not be able to lead to a definitive 
diagnosis of AR, may enable pharmacists to determine whether a diagnosis of AR should be further 
investigated and can assist in identifying warning symptoms that need further medical investigation. 
Figure 2 summarises the list of symptoms, which, if they occur in isolation, may be suggestive of a 
condition other than AR. The key feature of AR to remember is that AR symptoms are never 
unilateral and minimal bleeding may occur during long-term intranasal therapy. Furthermore, 
although nasal obstruction, loss of smell (80), facial pain or post nasal drip may be AR symptoms, 
when they occur as single symptoms, they are unlikely to be from allergic origin. Purulent discharge, 
especially if accompanied with fever, is suggestive of an infection (Figure 2). AR may present with 
symptoms similar to those of a number of other conditions induced by non-allergic triggers including 
viral infections such as the common cold. Table 2 may help the pharmacist to differentiate allergy 
from other causes including infection. 
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The ARIA guideline proposes a classification of AR based on symptom control, QOL and daily impact 
as well as duration (7, 44). Disease control associated with several health outcomes, including QOL 
(59-63) and some mHealth endpoints (72, 81-84), should be considered in ICPs. Although the 
duration of rhinitis is an important indicator of asthma multimorbidity (85), and duration and 
efficacy of treatment in AR (61), AR control should be considered as the most important end point 
for the pharmacist. 
AR ‘control” in AR patients is the main goal of treatment (86). Control is the degree to which therapy 
goals are currently met such as glycaemic control in diabetes. However, measures of AR control are 
somewhat different to many other chronic diseases as while they include symptom scores, 
alternative scales/scores, which are reflective of the impact of AR on day-to-day living, have been 
shown to be validated as measure of AR control. For example visual analogue scales (VAS) assessing 
impact of AR (69, 87), quality of life (QOL) measures and scores with several items which cover 
symptoms and impact on daily living (88, 89) are commonly used. In deciding which measure of AR 
control is most appropriate, it is important for a score to be simple and responsive to change over 
time, as AR control changes, hence VAS scores, which can be used in all age groups, (90, 91) are 
available in a wide variety of languages (92, 93) and have been shown to be valid for assessing AR 
control, are useful instruments for assessing AR control (Figure 3).    
A VAS (range: 0-20) can be used to assess control before and some days after treatment (Figure 6). If 
the scale is <20/100, the patient has controlled AR, if the scale is from 20 to 50/100, the patient has 
partly controlled disease and for ≥50/100, the patient has uncontrolled disease (Figure 6). Using VAS 
can help the pharmacist to assess response to OTC treatment. VAS can be used to assess overall AR 
control (VAS global measure) as it relates to nasal symptoms and eye symptoms (94) (Figure 3 and 
Figure 6). There is a high degree of correlation between VAS global measured (“Overall how much 
are your allergic symptoms bothering you today?”) and VAS for nose symptoms (81, 84). An 
electronic form of the VAS exists in the Allergy Diary (81, 84) and has been validated against several 
end points. 
b. Identification of AR-related ocular symptoms and asthma  
Ocular symptoms are commonly associated with nasal symptoms in AR, and they can be diagnosed 
using simple questions. However, some forms of conjunctivitis require referral to a physician (Figure 
4). A VAS for ocular symptoms may also be used and is included in the Allergy Diary (Figure 3). 
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Asthma is a common multi-morbidity of AR and should be checked. A proposal has been made in 
ARIA in the pharmacy (23) (Figure 5). All patients with rhinitis should be evaluated for asthma, 
particularly if they have persistent and/or moderate-severe rhinitis. 
 
c. AR Treatment 
Goals for the treatment of rhinitis should be determined after an accurate diagnosis of AR and a 
validated assessment of control, including evaluation of coexisting asthma.  AR treatment goals 
include: 
• Normal sleep. 
• Ability to undertake normal daily activities, including work and school attendance, without 
limitation or impairment, and the ability to participate fully in sport and leisure activities. 
• No troublesome symptoms. 
• No or minimal side-effects of rhinitis treatment. It should be recognized that many OTC drugs for 
the treatment of AR can induce sedation and should be avoided. 
In all guidelines, it has been considered that many medications may be used at several steps of 
severity and duration (44); including antihistamines (oral and intranasal), intranasal 
glucocorticosteroids (INCS) leukotriene receptor antagonists and chromones (intranasal and eye 
drops). Anticholinergics and decongestants (intranasal and oral) are sometimes noted in the 
treatment of AR on a short-term basis however, there is little good quality evidence for their 
effectiveness (45) and prolonged use of decongestants (>10 days) may lead to rebound swelling of 
the nasal mucosa, drug-induced rhinitis (also known as rhinitis medicamentosa) and tachyphylaxis 
(7). Table 3 summarises the specific pharmacological effects of these different agents on specific AR 
symptoms (95).  
In consideration of the specific role of the pharmacist, however, it is important to focus on 
pharmacotherapy that it available OTC in pharmacies i.e. antihistamines and in some countries, 
intranasal corticosteroids. Considering OTC medications, intra-nasal corticosteroids (INCS) are more 
effective than oral or intranasal H1-antihistamines (27, 44) but many patients prefer oral drugs. 
Other medications include leukotriene antagonists, nasal washing, vasoconstrictors and 
cromoglycate.  In some countries (currently in New Zealand), the combination of azelastine and 
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fluticasone propionate is OTC. This medication may be preferred if the patient wants a rapid onset of 
action of the treatment (26). 
Figure 6 provides a clinical treatment pathway to help pharmacists choose the appropriate OTC 
medications, based on assessment of AR control using VAS. The patient’s preference should always 
be considered. OTC medication availability differs between countries. 
Immunotherapy and AR treatment: The application of both subcutaneous immunotherapy and 
sublingual immunotherapy (for treatment of allergies to pollens, ragweed and house dust might) are 
reserved for patients with severe AR. They have been shown to improve the quality of life of people 
with AR and reduce the need for other pharmacological therapy (96-98). Currently in most countries, 
initiation of immunotherapy is both administered and monitored by specialist physicians. The role of 
pharmacy within the context of this treatment has not as yet been defined. 
Non pharmacological AR treatment: In addition to pharmacological treatment, historically patients 
with AR have been recommended non-pharmacological strategies such as allergen avoidance or 
minimisation and nasal washing. When it comes to seasonal AR, it is evident that avoidance of 
seasonal allergens is effective. i.e. patients with seasonal AR do not experience symptoms outside of 
season. However, while the level of evidence is low, during pollen season, patients can be advised to 
close windows at night, drive with closed windows and wear wrap-around glasses when outdoors, to 
prevent exacerbation of symptoms; ,and wear sunglasses (99), nasal filters (100) and apply balms 
and ointments to the nose (95) during pollen season  to reduce symptoms. For patients with 
occupational AR, avoiding exposure to the occupational agent trigger AR is recommended (101). 
There is limited evidence that saline washings, irrigation or sprays are effective in reducing AR 
symptoms and potentially reducing the amount of pharmacotherapy needed (7, 102) however, they 
are well tolerated, safe and inexpensive(103), hence for patients who would like to try them, they 
can be safely recommended. 
d. Patient Support and AR monitoring over time 
In considering the way in which pharmacists can support the patient with AR, it is important to build 
on the process of recognition, classification and treatment recommendations with appropriate 
education, self-management support and both short and long term monitoring.  
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Education around the condition of AR is fundamental, however, education about the way in which 
treatment works, the need to be both adherent and use intranasal devices correctly, is also critical. 
In particular, it is well recognized that non-adherence to AR treatment adds to the burden of 
disease. It is difficult to accurately determine non-adherence to AR treatment, as some medications 
are taken seasonally (as needed) and many are available over the counter in the pharmacy. It is, 
however estimated that for people using intranasal corticosteroids to treat their AR, adherence is 
approximately 35% (104). Supporting the patient to better understand the way in which medication 
works and the need to take it regularly is critical. It has been shown that when pharmacists work 
with patients to assist them in setting their goals for AR management, better long term AR outcomes 
are achieved (36, 37) 
Further to this, patients must be shown how to use their intranasal sprays correctly. Little is known 
about the proportion of patients who use their intranasal medication correctly however, the way in 
which the patient uses their intranasal spray does impact on way in which the spray distributes in 
the nasal cavity (105) and the occurrence of local side effects (106). Therefore, as with asthma 
devices, it is recommended that pharmacists train the patient how to use their intranasal device 
with a placebo device. 
Monitoring adherence with AR treatment is a challenge.  This is where the use of technology can 
assist. There are several mHealth tools for AR follow up but only the Allergy Diary has been 
validated. The Allergy Diary (MASK-rhinitis) has been implemented in 23 countries and 16 languages. 
Over 23,000 users have been recorded (55, 81, 82, 107-111). This tool appears to be appropriate for 
pharmacists, in particular since it is extremely simple, does not require the pharmacist to undertake 
any particular education on its use, is user friendly for the patient and can be used for follow-up over 
time. 
For confidentiality reasons, patients cannot give access of the electronic data that they record in the 
Allergy Diary (both symptom VAS and medication use) to HCPs. However, they can print their daily 
AR control VAS responses and medication use, as summarized in Figure 7.  Comparison of control at 
first dispensing of an OTC medication with the evolution of control during treatment will guide 
pharmacists to stop or increase the treatment with OTC medications or suggest referral to a 
physician. Moreover, this control chart will help the physician to optimize the treatment.  
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Conclusion 
The present paper has summarized the need for community pharmacists to play an important role in 
ICPs for AR. Although each recommendation varies between countries due to the available OTC 
medications, legislation and cultural differences, ARIA-Pharmacy may be used as a model for the 
implementation of ICPs in different countries. 
 
Table 1: Importance of pharmacists in the management of allergic rhinitis  
• Recognizing (identification of) AR  
• Risk assessment/stratification  
• Over-the-counter treatment  
• Patient education 
• Referral to a physician  
• Administration of topical treatment technique, Including teaching and re-evaluation of treatment 
technique 
• Adherence to treatment 
• Research on database 
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Table 2: Is it a cold or allergic rhinitis? 
Symptoms Cold Allergic rhinitis 
Duration 5-10 days Variable but can last months or present recurrent 
episodes  
Season Most often in winter but may be 
possible at any time 
Any time of the year, more common during 
pollen seasons which can occur in winter 
Course of the 
disease 
Symptoms usually take a few hours or 
days to be severe 
Symptoms can be severe within minutes 
Nasal and ocular 
symptoms 
• Severe nasal obstruction 
• Rhinorrhoea   
• Sneezing (rarely in bouts) 
• NO nasal or ocular pruritus 
• Rare ocular symptoms 
• Frequent loss of smell 
• Profuse watery rhinorrhoea 
• Several episodes of sneezing in succession 
• Nasal pruritus 
• Variable nasal congestion 
• Often associated with ocular symptoms 
(tearing, redness, pruritus) 
• Partial loss of smell in the most severe 
patients 
Sore Throat Common Sometimes 
Cough Common Sometimes 
Chest Discomfort • Mild to moderate 
• Cold can lead to severe asthma 
exacerbation 
Rare, except for those with allergic asthma 
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Table 3: AR symptoms and relative effectiveness of different pharmacotherapeutic agents (from 
(95, 112) 
 Sneezing Rhinorrhea 
Nasal 
obstruction 
Nasal itch Eye symptoms 
Hi-
antihistamines 
     
Oral ++ ++ + +++ ++ 
Intranasal ++ ++ + ++ 0 
Eye drops 0 0 0 0 +++ 
Corticosteroids      
Intranasal +++ +++ ++ ++ ++ 
Chromones      
Intranasal + + + + 0 
Eye drops 0 0 0 0 + 
Decongestants      
Intranasal 0 0 ++++ 0 0 
Oral 0 0 + 0 0 
Anti-cholinergics 0   0 0 
Anti-leukotrienes 0   0 ++ 
Intranasal 
steroids and 
intranasal 
antihistamine 1 
+++ +++ +++ +++ +++ 
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Figure 1: ARIA in the pharmacy initiative for AIRWAYS ICPs in allergic rhinitis (modified from (66)) 
 
This is a generic algorithm which varies between countries depending on regulations. 
The health care professional should ascertain that the treatment taken by the patient accords to best practices. In 
particular, regular use of short-acting ß2 agonist as a single treatment should be avoided. Similarly, prolonged use of intra-
nasal vasoconstrictors in rhinitis should be avoided. 
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Figure 2: Diagnosis of allergic rhinitis in the pharmacy (Adapted from (23)) 
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Figure 3: The MASK Allergy Diary 
 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Figure 4: Diagnosis of allergic conjunctivitis at the pharmacy (adapted from (23) 
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Figure 5: Screening of asthma in rhinitis patients in the pharmacy (from (23)) 
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Figure 6: Treatment of allergic rhinitis in the pharmacy (adapted from (23))  
 
 VAS nose: “How are your nose symptoms bothering you today?” 
*INCS if coexisting asthma. 
AH antihistamine; INCS intranasal corticosteroid; INAH intranasal antihistamine. 
VAS eyes: “How are your eye symptoms bothering you today?” 
*INCS if coexisting asthma. 
IOAH intraocular antihistamine; INCS intranasal corticosteroid. 
This algorithm should be adapted to the regulations, needs, price of medications and cultural barriers of each 
country (or region) 
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Figure 7: Transfer of patient information on a computer and printed information (From  (109))  
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